Amalgamated Financial’s Inovio Pharmaceuticals INO Stock Holding History

Amalgamated Financial’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$89K	Buy	+2,074	New	+$93.4K	﹤0.01%	2190

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Financial's INO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Inovio Pharmaceuticals (INO) in Q1 2022: 2,074 shares worth $89K. The stake represents ﹤0.01% of the portfolio and ranks #2190 among its holdings.

198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

Amalgamated Financial held 2,074 shares of Inovio Pharmaceuticals worth $89K as of Q1 2022.
Inovio Pharmaceuticals was a new Amalgamated Financial position in Q1 2022.
Inovio Pharmaceuticals made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2190 holding.
198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.